1．本次股东大会不存在否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席的情况 （一）会议召开情况 证券代码：301239 证券简称：普瑞眼科 公告编号：2025-030 成都普瑞眼科医院集团股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 3．会议召开的方式：本次股东大会采用现场投票与网络投票相结合的方式 召开。 4．会议召集人：成都普瑞眼科医院集团股份有限公司（以下简称"公司"） 董事会。 5．会议主持人：公司董事长徐旭阳先生。 1．会议召开时间 6．本次股东大会的召集和召开程序符合有关法律、法规、规范性文件及 《公司章程》的有关规定。 （1）现场会议时间：2025年5月20日（星期二）15:00； （二）会议出席情况 （2）网络投票时间 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年5月20 日9:15-9:25、9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系 统进行网络投票的时间为：2025年5月20日9:15- ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于成都普瑞眼科医院集团股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2024]A0248 号 致：成都普瑞眼科医院集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《成都普瑞眼科医院 集团股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开 程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等 ...

证券代码：301239 证券简称：普瑞眼科 成都普瑞眼科医院集团股份有限公司 投资者关系活动记录表 编号：2025-001 | 投资者关系活动 | | □特定对象调研□分析师会议 | | --- | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | | □新闻发布会□路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2025 年 5 月 19 日 (周一) 下午 15:00~16:00 | | | 地点 | 网络远程 | | | 上市公司接待人 | 董事长：徐旭阳 | | | 员姓名 | 副总经理、董事会秘书：金亮 | | | | 财务负责人：杨国平 | | | | 独立董事：邹欢 | | | | 保荐代表人：李沁杭 1、请问公司如何看待行业未来的发展前景？ | | | | 答：眼科医疗服务行业未来发展机遇与挑战并存。首先，眼科市 场规模持续扩大。随着老龄化加速，白内障患者增多，手术市场 | | | | 规模将不断扩大；青少年近视防控形势严峻，医学视光市 ...

证券代码：301239 证券简称：普瑞眼科 公告编号：2025-029 成都普瑞眼科医院集团股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押的基本情况 注：（1）上表中"占其所持股份比例"的合计数为本次质押后累计质押股份总数占控 股股东及其一致行动人所持有公司股份总数的比例； （2）浦视玖昊指上海浦视玖昊企业管理合伙企业（有限合伙）；浦视捌昊指上海 浦视捌昊企业管理合伙企业（有限合伙）；浦视伍昊指上海浦视伍昊企业管理合伙企 业（有限合伙）；浦视叁昊指上海浦视叁昊企业管理合伙企业（有限合伙）； （3）本公告中出现总数与各分项数值之和尾数不符的情况，均为四舍五入原因造 成。 二、其他说明 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 股 东 名 称 持股数 量 （股） 持 股 比 例 本次质 押前质 押股份 数量 （股） 本次质 押后质 押股份 数量 （股） 占 其 所 持 股 份 比 例 占 公 司 总 股 本 比 例 已质押股份 情况 未质押股份 情况 已质押 股份限 售和冻 结数量 ...

为便于广大投资者更加全面深入地了解公司经营管理情况，公司定于2025 年5月19日（星期一）15:00-16:00在深圳证券交易所"互动易"平台"云访谈" 栏目举办2024年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方 式举行，投资者可登陆深圳证券交易所"互动易"平台（irm.cninfo.com.cn）， 进入"云访谈"栏目参与本次业绩说明会。 公司拟出席本次业绩说明会的人员有：公司董事长徐旭阳先生、独立董事 邹欢先生、副总经理兼董事会秘书金亮先生、财务负责人杨国平先生、保荐代 表人李沁杭先生（如遇特殊情况，参会人员可能进行调整）。 为进一步做好中小投资者保护工作，增进投资者对公司的了解，现就公司 2024年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议 ， 提 升 交 流 效率和 针 对 性 。 投 资 者 可 提 前 登 录 " 互 动 易 " 平 台 （irm.cninfo.com.cn）"云访谈"栏目进入公司本次业绩说明会页面进行提问。 公司将在2024年度业绩说明会上在信息披露允许范围内对投资者普遍关注的问 题进行回答。 本公司及董事会全体成员保证信息披露的内容真实、 ...

Core Viewpoint - As of May 8, 2025, the stock price of Puri Eye Hospital (301239) closed at 43.0 yuan, reflecting a decrease of 1.17% with a turnover rate of 2.33% and a trading volume of 16,500 shares, amounting to a transaction value of 71.48 million yuan [1]. Group 1: Business Operations - Puri Eye Hospital operates as a large-scale non-public ophthalmology specialty medical group, with all its hospitals included in the medical insurance designated point system [2]. - The company has a dual pricing logic for its products and services: it has full pricing autonomy for selective consumer projects and high-end examinations (outside the medical insurance catalog), while it strictly adheres to national medical insurance cost control policies for basic treatments and routine examinations (within the medical insurance catalog) [2]. - The company is leveraging the benefits of medical insurance cost control policies, such as centralized procurement price reductions and optimized payment methods, to enhance the accessibility and affordability of eye disease treatments for patients [2]. Group 2: Financial Flow - On May 8, 2025, the financial flow for Puri Eye Hospital showed a net outflow of 3.06 million yuan from major funds and a net outflow of 2.09 million yuan from speculative funds, while retail investors saw a net inflow of 5.15 million yuan [2].

Group 1 - The core viewpoint of the news highlights the financial performance and market position of Puri Eye Hospital Group, indicating a recent stock price increase and a significant market capitalization of 6.586 billion yuan [1] - As of May 6, the stock closed at 44.02 yuan, reflecting a 2.28% increase, with a latest price-to-book ratio of 3.09, marking a new low in 16 days [1] - The company experienced a net outflow of 976,800 yuan in principal funds on May 6, with a total outflow of 23.9214 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - In the first quarter of 2025, the company reported an operating income of 742 million yuan, representing a year-on-year increase of 9.82%, and a net profit of 27.2794 million yuan, which is a 61.18% increase compared to the previous year [2] - The company's sales gross margin stands at 39.34%, which is a critical indicator of its profitability [2] - The company has a price-to-earnings ratio (TTM) of -71.97, which is significantly lower than the industry average of 38.66, indicating potential undervaluation in the market [2]

证券研究报告·公司点评报告·医疗服务 普瑞眼科（301239） 2024 年年报及 2025 年一季报点评：Q1 业绩 符合预期，新院爬坡有望带来业绩改善 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 2,718 | 2,678 | 2,989 | 3,306 | 3,656 | | 同比（%） | 57.50 | (1.46) | 11.60 | 10.61 | 10.58 | | 归母净利润（百万元） | 267.91 | (101.86) | 104.09 | 194.76 | 252.38 | | 同比（%） | 1,202.56 | (138.02) | 202.19 | 87.11 | 29.58 | | EPS-最新摊薄（元/股） | 1.79 | (0.68) | 0.70 | 1.30 | 1.69 | | P/E（现价&最新摊薄） | 23.95 | (62.98) | 61.64 | 32 ...

Core Insights - The company experienced a decline in revenue and profit in 2024, with operating income of 2.678 billion yuan (-1.46% year-on-year) and a net profit attributable to shareholders of -102 million yuan (-138.02%) [1] - In Q1 2025, the company showed signs of recovery with operating income of 742 million yuan (+9.82%) and a net profit attributable to shareholders of 27 million yuan (+61.18%) [1] Financial Performance - In 2024, the company reported a total outpatient volume of over 1.531 million visits (+1.63%) and over 181,200 surgeries (+3.13%) [1] - Revenue from refractive services in 2024 was 1.227 billion yuan (-5.31%) with a gross margin of 47.02% (-4.56 percentage points) [1] - The company’s overall sales gross margin and net margin for 2024 were 36.98% and -3.47%, respectively, reflecting a year-on-year decline of 7.02 and 13.70 percentage points [2] Business Segmentation - The company’s cataract revenue in 2024 was 576 million yuan (-3.04%) with a gross margin of 38.93% (-4.44 percentage points) [1] - Comprehensive eye disease revenue increased by 12.81% to 470 million yuan, although the gross margin decreased to 0.47% (-12.94 percentage points) [1] Strategic Developments - As of the end of 2024, the company operated 35 ophthalmology specialty hospitals and 4 outpatient departments, with 16 new medical institutions added from 2022 to 2024, accounting for over 40% of total facilities [2] - The company is in a market cultivation phase for its newly opened hospitals, which has led to increased fixed costs and pressure on profits [2] Profit Forecast - The company revised its net profit forecasts for 2025-2026 down to 104 million yuan and 195 million yuan, respectively, from previous estimates of 207 million yuan and 301 million yuan [3] - The projected net profit for 2027 is 252 million yuan, with corresponding price-to-earnings ratios of 62, 33, and 25 times for the respective years [3]

Group 1 - The company reported a revenue of 2.678 billion yuan in 2024, a year-on-year decrease of 1.46%, and a net profit attributable to shareholders of -102 million yuan, a decline of 138.02% [1] - In Q1 2025, the company achieved a revenue of 742 million yuan, a year-on-year increase of 9.82%, and a net profit attributable to shareholders of 27 million yuan, a growth of 61.18% [1] - The company expects a recovery in 2025, driven by improved consumer environment and policy support [2] Group 2 - In 2024, the company's revenue from refractive projects was 1.227 billion yuan, down 5.31% year-on-year, while cataract project revenue was 576 million yuan, down 3.04% [2] - The gross margin for refractive projects in 2024 was 47.02%, a decrease of 4.56 percentage points compared to the same period in 2023 [2] - The overall gross margin in 2024 was 36.98%, down 7.02 percentage points year-on-year, with a net margin of -3.47%, a decline of 13.7 percentage points [3] Group 3 - The company anticipates net profits of 118 million yuan, 197 million yuan, and 255 million yuan for the years 2025, 2026, and 2027 respectively, reflecting adjustments due to factors like artificial crystal procurement and DRG policy [4] - The company is positioned as a leading private ophthalmology medical enterprise in China, with clear expansion plans in provincial capitals [4] - The aging population is expected to drive demand for medical services, supporting the company's growth trajectory [4]